Express Pharma

OCTOBER 16, 2024

Manufacturing costs in India are also 30 – 35 per cent lower than those in the US and Europe (5), further sweetening the deal for global pharmaceutical companies. Biocon Biologics gained EMA approval to manufacture biosimilar Bevacizumab at its advanced facility in Bengaluru, enhancing its credibility internationally.

Biosimilars 103

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 103

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

Pharmaceutical Technology

JANUARY 16, 2023

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Free Report.

Drug Pricing 64

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64

Pharmaceutical Technology

JANUARY 16, 2023

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Free Report.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

European Pharmaceutical Review

JULY 4, 2024

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 2024 [cited 2024May]. Available from: [link] Legislation [Internet].

Drug Development 103

Drug Development Biosimilars Documentation Compounding 103

Express Pharma

JULY 15, 2024

This would encourage pharmaceutical companies to enhance their R&D efforts, bolstering India’s status as a global leader in innovative healthcare solutions. ” Dr Harshit Jain, Founder & Global CEO, Doceree: “Budget 2024 is a defining moment for the pharmaceutical sector in India.

Medical Records 105

Medical Records Biosimilars Pharmaceutical Companies Pharmaceutical Companies 105

European Pharmaceutical Review

FEBRUARY 26, 2024

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. CHMP meeting highlights: January 2024 The post CHMP meeting highlights: February 2024 appeared first on European Pharmaceutical Review.

Generic Medicine 98

Generic Medicine Vaccines Pharmaceutical Companies Pharmaceutical Companies 98

Pharmaceutical Technology

SEPTEMBER 26, 2022

The company told GlobalData PharmSource: “The biosimilar facilities in Austria and Slovenia would continue to manufacture biosimilars for Sandoz under a contractual agreement with Novartis. The company had revenues of $9.6bn both in 2020 and last year. The site employs around 250 people.

Biosimilars 64

Biosimilars Drug Development Vaccines Dosage 64

PharmaShots

MARCH 29, 2023

Shots: Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years.

Biosimilars 49

Biosimilars Diabetes Chemotherapy Immunization 49